GRK2 Breakthrough Could Redirect Alzheimer’s Treatment Path
TL;DR
ETH Zurich researchers identify inactive GRK2 aggregates that disrupt mitochondrial energy and drive amyloid beta buildup in Alzheimer’s, forming a damaging feedback loop. They developed Compound 10, which blocks GRK2 aggregation, preserves mitochondrial function, reduces amyloid beta, and slows nerve-cell loss in mice, suggesting a new upstream therapeutic approach that could complement existing treatments; a patent has been filed and industry partnerships are being pursued.
- New Alzheimer’s Discovery Could Change How Scientists Fight the Disease SciTechDaily
- Scientists found a new Alzheimer’s trigger and a drug that stops it ScienceDaily
- Scientists Found 2 Existing Drugs Could Reverse Alzheimer's Brain Damage in Mice ScienceAlert
- New drug could slow the development of Alzheimer's Medical Xpress
- New drug to slow Alzheimer’s development — and more health headlines WGN-TV
Want the full story? Read the original reporting
Read on SciTechDaily